Media

[image_with_animation image_url=”9996″ animation=”Fade In” hover_animation=”none” alignment=”center” border_radius=”none” box_shadow=”none” image_loading=”default” max_width=”100%” max_width_mobile=”default” img_link=”https://endpts.com/fda-lifts-hold-on-maats-microbiome-therapy/”]

[image_with_animation image_url=”9994″ animation=”Fade In” hover_animation=”none” alignment=”center” border_radius=”none” box_shadow=”none” image_loading=”default” max_width=”100%” max_width_mobile=”default” img_link=”https://www.thepharmaletter.com/article/fda-lifts-clinical-hold-of-maat-pharma-s-lead-microbiome-therapeutic-trial”]

[image_with_animation image_url=”9849″ animation=”Fade In” hover_animation=”none” alignment=”center” border_radius=”none” box_shadow=”none” image_loading=”default” max_width=”100%” max_width_mobile=”default” img_link=”https://pharmaphorum.com/oncology/gut-microbiome-next-breakthrough-cancer”]https://pharmaphorum.com/oncology/gut-microbiome-next-breakthrough-cancer

[image_with_animation image_url=”9756″ animation=”Fade In” hover_animation=”none” alignment=”center” border_radius=”none” box_shadow=”none” image_loading=”default” max_width=”100%” max_width_mobile=”default” img_link=”https://investir.lesechos.fr/conseils-boursiers/conseils-actions/maat-pharma-lapproche-novatrice-du-microbiote-1909546″]https://investir.lesechos.fr/conseils-boursiers/conseils-actions/maat-pharma-lapproche-novatrice-du-microbiote-1909546

During the 8th Microbiome Movement – Drug Development Summit, held in London at the end of January, MicrobiomePost asked to Herve Affagard,…

(French only)[image_with_animation image_url=”9274″ animation=”Fade In” hover_animation=”none” alignment=”center” border_radius=”none” box_shadow=”none” image_loading=”default” max_width=”100%” max_width_mobile=”default” img_link=”https://www.bfmtv.com/economie/replay-emissions/good-morning-business/herve-affagard-maat-pharma-la-biotech-maat-pharma-poursuit-son-developpement-13-12_VN-202212130076.html”]

[image_with_animation image_url=”9189″ animation=”Fade In” hover_animation=”none” alignment=”center” img_link_target=”_blank” border_radius=”none” box_shadow=”none” image_loading=”default” max_width=”100%” max_width_mobile=”default” img_link=”https://www.mednous.com/news/fda-approves-first-faecal-microbiota-product”]Hervé Affagard, CEO and co-founder of MaaT Pharma,…

[image_with_animation image_url=”9174″ animation=”Fade In” hover_animation=”none” alignment=”center” img_link_target=”_blank” border_radius=”none” box_shadow=”none” image_loading=”default” max_width=”100%” max_width_mobile=”default” img_link=”https://www.labiotech.eu/trends-news/fda-approval-of-first-fecal-microbiota-product-rebyota-hailed-fantastic/”]Hervé Affagard, CEO and co-founder of MaaT Pharma,…

[image_with_animation image_url=”9106″ animation=”Fade In” hover_animation=”none” alignment=”center” img_link_target=”_blank” border_radius=”none” box_shadow=”none” image_loading=”default” max_width=”100%” max_width_mobile=”default” img_link=”https://www.labiotech.eu/interview/maat-pharma-microbome/”]